Cover Image
市場調查報告書

生技仿製藥的全球市場 - 2016∼2020年

Global Biosimilars Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 232659
出版日期 內容資訊 英文 152 Pages
訂單完成後即時交付
價格
Back to Top
生技仿製藥的全球市場 - 2016∼2020年 Global Biosimilars Market 2016-2020
出版日期: 2016年08月01日 內容資訊: 英文 152 Pages
簡介

生技仿製藥是專利到期後的原創生物醫藥品之後續品,具有與原藥一樣的MOA (作用機制) ,目的在治療同樣的對象疾病。生技仿製藥雖然具有與原創藥許多共通點但絕非完全一樣的藥品。生技仿製藥的全球市場預測在2016年到2020年這段期間,將以55.52%年複合成長率 (CAGR) 持續成長。

本報告涵蓋生技仿製藥的全球市場,透過推動市場成長要素和市場課題,市場趨勢,以及市場競爭情形的詳細調查,來進行市場現狀分析以及2016年到2020年的未來預測。

第1章 摘要整理

第2章 本報告涵蓋範圍

  • 市場概要
  • 主要供應商產品
  • 前提條件

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 序論

  • 市場相關重要事項
  • 生技仿製藥:概要
  • 生技仿製藥與低分子學名藥比較分析
  • 生技仿製藥的市場機會
  • 新加入企業的相關課題
  • 生技改良藥

第5章 研究開發平台上的各種醫藥品

第6章 市場概況

  • 市場概要
  • 波特的五力分析

第7章 生技仿製藥的全球市場 - 各適應症市場分類

  • 血液疾病用生技仿製藥的全球市場
  • 市場概要
  • 癌症治療用生技仿製藥的全球市場
  • 慢性疾病及自體免疫疾病用生技仿製藥的全球市場
  • 生長激素缺乏症用生技仿製藥的全球市場
  • 感染疾病用生技仿製藥的全球市場
  • 其他

第8章 生技仿製藥的全球市場 - 各終端用戶市場分類

  • 醫院
  • 藥局·藥店

第9章 生技仿製藥的全球市場 - 各地區市場分類

  • 從各地區來看生技仿製藥的全球市場 - 2015∼2020年
  • 歐洲·中東·非洲地區的生技仿製藥市場
  • 亞太地區的生技仿製藥市場
  • 南北美洲地區的生技仿製藥市場

第10章 生技仿製藥的全球市場 - 成長推動因素

  • 專利到期的醫藥品數的增加
  • 成本效益高治療的需求
  • 保險對生技仿製藥的給付優勢
  • 有利的政府法規
  • 具有高未來性的研究開發平台階段的醫藥品

第11章 推動市場成長要素帶來的影響

第12章 生技仿製藥的全球市場 - 課題

  • 醫生對生技仿製藥的處方之抗拒感
  • 製造上的許多複雜性
  • 製作出無效醫藥品的風險
  • 生技仿製藥的難以取得
  • 在進行臨床試驗時難以募集受驗者

第13章 推動市場成長要素和市場課題帶來的影響

第14章 生技仿製藥的全球市場 - 趨勢

  • 生技仿製藥的崛起
  • 生技仿製藥製造的外包
  • 進行研究開發需要的大量投資需求
  • 新興各國市場上高成長
  • 策略性企業聯盟數量的增加

第15章 業者情勢

  • 市場競爭方案
  • Sandoz
  • Hospira
  • Teva Pharmaceuticals
  • STADA
  • Biocon
  • Celltrion
  • Dr. Reddy's
  • 其他卓越供應商

第16章 附錄

第17章 關於Technavio

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR10077

About Biosimilars

Biosimilars are defined as the follow-on versions of original biological medicines. These are separately developed after the patent protecting the original product has expired. Biosimilars are intended to have the same MOA as original biological drugs and are designed to treat the same diseases as the innovator's product. They have many similarities, but are not identical to, the reference biopharmaceutical product.

Technavio's analysts forecast the global biosimilars market to grow at a CAGR of 55.52% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global biosimilars market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of products such as somatropin, erythropoietin, colony-stimulating factors (CSF), interferons, interleukins, insulin and insulin analogs, follicle stimulating hormones (FSH), monoclonal antibodies (mAbs), and low molecular weight heparins (LMWH).

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Biocon
  • Celltrion
  • Dr. Reddy's Laboratories
  • Hospira
  • Sandoz
  • STADA
  • Teva Pharmaceuticals

Other Prominent Vendors

  • 3SBio
  • Accord Healthcare
  • AET Biotech
  • Allergan
  • Alvartis Pharma
  • Amega Biotech
  • Amgen
  • Apotex
  • Aspen
  • AstraZeneca
  • Aurobindo Pharma
  • Baxter
  • Bharat Serums
  • Bio Sidus
  • Biogen
  • Bionovis
  • Bioton
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Boston Oncology
  • Cipla
  • Coherus Biosciences
  • Daiichi Sankyo
  • Emcure Pharmaceuticals
  • Gedeon Richter
  • GeneScience Pharmaceuticals
  • GSK
  • Hetero Drugs
  • iBio
  • Intas Pharmaceuticals
  • JCR Pharmaceuticals
  • LG Lifesciences
  • Lonza
  • Merck
  • Mitsubishi Tanabe Pharma
  • Momenta Pharmaceuticals
  • Mylan
  • Natco Pharma
  • Novartis
  • Pfenex
  • Pfizer
  • Ranbaxy Laboratories
  • Roche Holding
  • Samsung Biologics
  • Sanofi
  • Synthon
  • Wockhardt
  • Zydus Cadila Healthcare

Market driver

  • Rise in number of patent expiries
  • For a full, detailed list, view our report

Market challenge

  • Physicians reluctance to prescribe biosimilars
  • For a full, detailed list, view our report

Market trend

  • Emergence of biosimilars
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings
  • Assumptions

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Biosimilars: Overview
  • Comparative analysis of biosimilars and generic small molecules
  • Biosimilars market opportunities
  • Challenges for new entrants
  • Bio-betters

PART 05: Pipeline portfolio

PART 06: Market landscape

  • Market overview
  • Five forces analysis

PART 07: Market segmentation by application

  • Global blood disorders biosimilars market
  • Market overview
  • Global oncology biosimilars market
  • Global chronic and autoimmune diseases biosimilars market
  • Global growth hormone deficiency biosimilars market
  • Global infectious diseases biosimilars market
  • Others

PART 08: Market segmentation by end-user

  • Hospitals
  • Retail pharmacies

PART 09: Geographical segmentation

  • Global biosimilars market by geographical segmentation 2015-2020
  • Biosimilars market in EMEA
  • Biosimilars market in APAC
  • Biosimilars market in Americas

PART 10: Market drivers

  • Rise in number of patent expiries
  • Need for cost-effective treatment
  • Reimbursement benefits for biosimilars
  • Favorable government regulations
  • Promising pipeline

PART 11: Impact of drivers

PART 12: Market challenges

  • Physicians reluctance to prescribe biosimilars
  • Multiple manufacturing complexities
  • Risks related to drug failure
  • Limited availability of biosimilar products
  • Difficulties in patient recruitment for conducting clinical trials

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Emergence of biosimilars
  • Outsourcing of biosimilar manufacturing activities
  • Need for high investment in R&D
  • High growth in the emerging markets
  • Rising number of strategic collaborations

PART 15: Vendor landscape

  • Competitive scenario
  • Sandoz
  • Hospira
  • Teva Pharmaceuticals
  • STADA
  • Biocon
  • Celltrion
  • Dr. Reddy's
  • Other prominent vendors

PART 16: Appendix

  • List of abbreviations

PART 17: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global biosimilar market snapshot
  • Exhibit 03: Key buying criteria for biosimilars 2015
  • Exhibit 04: Major timelines in global biosimilars market 2014-2020
  • Exhibit 05: Impact of key customer segments on market 2015
  • Exhibit 06: Definition of biosimilars in different regions
  • Exhibit 07: Comparison between biosimilars and generic small molecules
  • Exhibit 08: Factors affecting biologics and biosimilars market
  • Exhibit 09: Impact of biosimilars cost savings on various sectors
  • Exhibit 10: Factors affecting success of biosimilars
  • Exhibit 11: Biosimilars industry: Point-of-view
  • Exhibit 12: Factors influencing uptake of biosimilars
  • Exhibit 13: Global biosimilars market: Strategic factors for new market entrants
  • Exhibit 14: Challenges for new entrants
  • Exhibit 15: Bio-betters and its impact on market
  • Exhibit 16: Global biosimilars market: Pipeline snapshot 2015
  • Exhibit 17: Pipeline portfolio: Global biosimilars market 2015
  • Exhibit 18: Number of approved biosimilars in regulated and semi-regulated markets
  • Exhibit 19: Patent expirations of major biologics from 2000-2030
  • Exhibit 20: Global biosimilars market snapshot: Developed and emerging markets 2015
  • Exhibit 21: Patient assistance programs by vendors
  • Exhibit 22: Global biosimilars market 2015-2020 ($ billions)
  • Exhibit 23: Global spending for biosimilars 2015-2020 ($ billions)
  • Exhibit 24: Global biosimilars market: Key metrics analysis snapshot
  • Exhibit 25: Current and future trends in global biosimilars market
  • Exhibit 26: Impact of drivers and challenges on global biosimilars market
  • Exhibit 27: Five forces analysis
  • Exhibit 28: Global biosimilars market: Segmentation by application (2015-2020)
  • Exhibit 29: Applications of biosimilars and its impact on growth of market
  • Exhibit 30: Global biosimilars market: Segmentation by application 2015
  • Exhibit 31: Global biosimilars market segmentation: Growth cycle analysis
  • Exhibit 32: Global blood disorders market biosimilar 2015-2020 ($ billions)
  • Exhibit 33: Opportunity analysis of global blood disorders biosimilar market by type of application
  • Exhibit 34: Global oncology biosimilar market 2015-2020 ($ billions)
  • Exhibit 35: Opportunity analysis of global oncology biosimilar market by type of application
  • Exhibit 36: Population aged 60 years and over (millions)
  • Exhibit 37: Global chronic and autoimmune diseases biosimilars market 2015-2020 ($ millions)
  • Exhibit 38: Opportunity analysis of chronic and autoimmune diseases biosimilars market by application
  • Exhibit 39: Global growth hormone deficiency biosimilars market 2015-2020 ($ millions)
  • Exhibit 40: Opportunity analysis of global growth hormone deficiency biosimilars market
  • Exhibit 41: Global infectious diseases biosimilars market 2015-2020 ($ millions)
  • Exhibit 42: Opportunity analysis of infectious diseases biosimilars market by application
  • Exhibit 43: Global biosimilars market segmentation by application 2015
  • Exhibit 44: Biosimilars market segmentation by end-user 2015
  • Exhibit 45: Global biosimilars market: Geography outlook (2015-2020)
  • Exhibit 46: Global biosimilars market: Geography outlook 2015
  • Exhibit 47: Revenue/growth outlook in different countries/regions 2015
  • Exhibit 48: Biosimilar market landscape: Country analysis
  • Exhibit 49: Market penetration of originators and biosimilars in different regions
  • Exhibit 50: Biosimilars market in EMEA 2015-2020 ($ billions)
  • Exhibit 51: Biosimilars market in EMEA by region 2015
  • Exhibit 52: Guidelines for biosimilars in EU
  • Exhibit 53: Timeline of biosimilars in Europe
  • Exhibit 54: Geographical segmentation in Europe 2015
  • Exhibit 55: Patent expirations of major biologics in Europe
  • Exhibit 56: Key leading countries in EMEA 2015
  • Exhibit 57: Biosimilars market in Europe 2015-2020 ($ billions)
  • Exhibit 58: Europe biosimilars market: Opportunity analysis
  • Exhibit 59: Approved marketed products in Europe
  • Exhibit 60: Key stake holders in EU biosimilars market
  • Exhibit 61: PEST analysis: Biosimilars market in Europe 2015
  • Exhibit 62: Biosimilars market in Germany 2015-2020 ($ millions)
  • Exhibit 63: Biosimilars market in UK 2015-2020 ($ millions)
  • Exhibit 64: Biosimilars market in France 2015-2020 ($ millions)
  • Exhibit 65: Biosimilars market in Italy 2015-2020 ($ millions)
  • Exhibit 66: Biosimilars market in Spain 2015-2020 ($ millions)
  • Exhibit 67: Biosimilars market in APAC 2015-2020 ($ billions)
  • Exhibit 68: Biosimilars market in APAC by country 2015
  • Exhibit 69: Key leading countries in APAC 2015
  • Exhibit 70: Biosimilars market in China 2015-2020 ($ millions)
  • Exhibit 71: China biosimilars market: Opportunity analysis
  • Exhibit 72: PEST analysis: Biosimilars market in China
  • Exhibit 73: Timeline for development of biosimilars in India
  • Exhibit 74: Challenges and strategies in developing biosimilars in India
  • Exhibit 75: Biosimilars market in India 2015-2020 ($ millions)
  • Exhibit 76: India biosimilars market: Opportunity analysis
  • Exhibit 77: Approved biosimilars in India
  • Exhibit 78: PEST analysis: Biosimilars market in India 2015
  • Exhibit 79: Review process for biosimilars in Japan
  • Exhibit 80: Biosimilars approved by PMDA in Japan
  • Exhibit 81: Biosimilars market in Japan 2015-2020 ($ millions)
  • Exhibit 82: Biosimilars market in Japan: Opportunity analysis
  • Exhibit 83: PEST analysis: Biosimilars market in Japan 2015
  • Exhibit 84: Biosimilars market in Americas 2015-2020 ($ billions)
  • Exhibit 85: Approvals of biologicals versus biosimilars via public health service act (PHSA)
  • Exhibit 86: Timeline of biosimilar regulations in US
  • Exhibit 87: Approval process for biosimilars in US
  • Exhibit 88: Benefits of biosimilars to US healthcare system
  • Exhibit 89: Patent expirations of major biologics in US
  • Exhibit 90: Biosimilars market in US 2015-2020 ($ million)
  • Exhibit 91: Biosimilars market in US: Opportunity analysis
  • Exhibit 92: Role of stakeholders in creating awareness in US
  • Exhibit 93: PEST analysis: Biosimilars market in US 2015
  • Exhibit 94: Global biosimilars market: Key leading countries (2015)8
  • Exhibit 95: Patent analysis of biologicals in US
  • Exhibit 96: Patent analysis of biologicals in Europe
  • Exhibit 97: Impact of drivers
  • Exhibit 98: Key reasons as to why physicians are reluctant to prescribe biosimilar6
  • Exhibit 99: Impact of drivers and challenges
  • Exhibit 100: Global biosimilars market: Impact assessment of key trends
  • Exhibit 101: Competitive assessment of vendors
  • Exhibit 102: Key vendors: Geographical presence 2015
  • Exhibit 103: Mergers, acquisitions and partnership assessment of major vendors in global biosimilars market
  • Exhibit 104: Sandoz: YoY revenue and growth rate of biosimilars 2014-2015 ($ millions)
  • Exhibit 105: Sandoz: Metrics analysis
  • Exhibit 106: Hospira: Metrics analysis4
  • Exhibit 107: Teva Pharmaceuticals: Metrics analysis6
  • Exhibit 108: STADA: Metrics analysis
  • Exhibit 109: Biocon: Metrics analysis
  • Exhibit 110: Celltrion: Metrics analysis
  • Exhibit 111: Dr. Reddy's: Metrics analysis
Back to Top